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Abstract
Hyperuricemia is associated with renal stones, not only consisting of uric acid (UrAc) but also of calcium oxalate (CaOx). Gly-
cosaminoglycans (GAGs) are well-known inhibitors of growth and aggregation of CaOx crystals. We analyzed the effect of non-
crystalline UrAc on GAG synthesis in tubular distal cells. MDCK (Madin-Darby canine kidney) cells were exposed to noncrystalline 
UrAc (80 µg/mL) for 24 h. GAGs were labeled metabolically and characterized by agarose gel electrophoresis. The expression of 
proteoglycans and cyclooxygenase 2 (COX-2) was assessed by real-time PCR. Necrosis, apoptosis and prostaglandin E2 (PGE2) 
were determined by acridine orange, HOESCHT 33346, and ELISA, respectively. CaOx crystal endocytosis was evaluated by 
flow cytometry. Noncrystalline UrAc significantly decreased the synthesis and secretion of heparan sulfate into the culture medium 
(UrAc: 2127 ± 377; control: 4447 ± 730 cpm) and decreased the expression of perlecan core protein (UrAc: 0.61 ± 0.13; control: 
1.07 ± 0.16 arbitrary units), but not versican. Noncrystalline UrAc did not induce necrosis or apoptosis, but significantly increased 
COX-2 and PGE2 production. The effects of noncrystalline UrAc on GAG synthesis could not be attributed to inflammatory actions 
because lipopolysaccharide, as the positive control, did not have the same effect. CaOx was significantly endocytosed by MDCK 
cells, but this endocytosis was inhibited by exposure to noncrystalline UrAc (control: 674.6 ± 4.6, CaOx: 724.2 ± 4.2, and UrAc + 
CaOx: 688.6 ± 5.4 geometric mean), perhaps allowing interaction with CaOx crystals. Our results indicate that UrAc decreases 
GAG synthesis in MDCK cells and this effect could be related to the formation of UrAc and CaOx stones. 
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Kidney stones are composed of a mixture of inorganic 
and organic components, as well as proteins. Crystallization 
(and subsequently lithogenesis) may occur from different 
solutes in urine. Calcareous stones are the most common 
(80%), while uric acid (UrAc) stones represent only 5-10%, 
followed by cystine, struvite, and ammonium acid urate 
stones (1-3).
UrAc stones can result from either hyperuricosuria, 
acidic urine, or both (4,5). At low urine pH, UrAc can induce 
heterogeneous nucleation of calcium oxalate (CaOx). This 
mechanism constitutes the basis for potential hyperuricosu-
ric calcium urolithiasis. At high urine pH, solubility of UrAc 
increases (noncrystalline UrAc). Once considered as inert 
product and the main serum antioxidant, soluble UrAc has 
proinflammatory effects that can contribute to the develop-
ment of UrAc stones.
The urine is normally supersaturated with solutes, such 
as CaOx, calcium phosphate, sodium urate, and UrAc, 
among others. In non-stone formers, the supersaturation 
is maintained, without precipitation, as a result of urinary 
inhibitors such as magnesium, citrate, pyrophosphate, 
Tamm-Horsfall protein, and glycosaminoglycans (GAGs). 
Some inhibitors are able to inhibit nucleation, while others 
inhibit crystal growth and aggregation (6,7).
In humans, the main urinary GAGs are chondroitin 
sulfate (CS) and heparan sulfate (HS), with small amounts 
of dermatan sulfate and trace amounts of hyaluronic acid 
and keratan sulfate (8). It has been shown that GAGs inhibit 
the growth and aggregation of CaOx crystals in vitro (9). 
Our laboratory has shown that stone-forming subjects, both 
children and adults, have lower concentrations of urinary 
GAG (8). There is evidence suggesting that urinary CS 
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is of systemic origin (10), while urinary HS and, possibly, 
dermatan sulfate could be of systemic origin or come from 
the kidney and/or urinary tract.
HS is the main kidney GAG, occurring both as a cell 
surface proteoglycan (PG) of the syndecan and glypican 
families, and as perlecan, the main basement membrane 
proteoglycan (11). Furthermore, the expression of the core 
protein of four small PG - decorin, biglycan, fibromodulin, 
and lumican - has been observed in the renal interstitium, 
with accumulation around tubules. Low expression of these 
core proteins has also been observed in the mesangial 
matrix (12). Increased expression of dermatan sulfate PG 
has also been shown in experimental models of chronic 
renal failure (13) and diabetes mellitus (14).
In contrast, increased expression of syndecan-1, a cell 
surface HS-PG, has been demonstrated in rat kidney with 
CaOx nephrolithiasis (15). The increased expression of 
syndecan-1 and HS in a cell line derived from Madin-Darby 
canine kidney (MDCK) cells led to a decrease in CaOx 
attachment to these cells (16), suggesting a protective 
role for this PG in CaOx nephrolithiasis. MDCK, a cell line 
derived from the distal tubular epithelium, expresses many 
PGs, also found in the kidney cortex as HS-PG perlecan, 
agrin, and collagen XVIII, as well as the CS-PG biglycan, 
bamacan, and versican (17). These PGs are also associ-
ated with mammalian kidney tubules in vivo. 
Exposure of MDCK type I cells to UrAc crystals and 
soluble UrAc was associated with increased monohydrate 
CaOx crystal adhesion and this binding was inhibited by 
prostaglandin E2 (PGE2) supplementation and delayed by 
blockade of prostaglandin production (18). Soluble UrAc also 
has proinflammatory and deleterious effects on endothelial, 
vascular smooth muscle and proximal tubular cells such 
as proliferation, activation of mitogen-activated protein 
kinases (MAPK), chemokines (monocyte chemoattractant 
protein-1), and the inflammatory enzymes cyclooxygenase 
2 (COX-2) and prostaglandins (19). 
The objective of the present study was to determine the 
effects of noncrystalline UrAc on the synthesis of GAGs, 
on inflammation and on the endocytosis of CaOx crystals 
in MDCK cells.
Material and Methods
Cell culture
Madin-Darby canine kidney cells, which are derived 
from distal tubular epithelial cells, were obtained from the 
American Type Culture Collection (ATCC, USA). They were 
grown in Dulbecco’s modified Eagle’s medium (DMEM, 
Sigma-Aldrich, USA) containing 5% fetal bovine serum 
(FBS, Gibco, Life Technologies, USA), 24 mM NaHCO3, 
10 mM HEPES, and 10,000 U/L penicillin/streptomycin 
(Gibco). The cultures were incubated at 37°C in a humidi-
fied atmosphere containing 5% carbon dioxide.
At the semi-confluence stage, cells were detached from 
the plastic flasks with trypsin (0.05%; Cultilab, Brazil), cen-
trifuged, resuspended in DMEM and subcultured in 25-cm2 
plastic culture flasks for the experimental procedures.
Preparation of noncrystalline UrAc
UrAc (0.01 g), obtained commercially (Merck EGaA, 
Germany), was added to 100 mL ethanol (100 µg/mL) with 
continuous stirring for 24 h. UrAc crystals were dried, steril-
ized in ethylene oxide or steam autoclaved, and suspended 
in culture medium without FBS (100 mL). The suspension 
was sonicated for 15 min to dissolve UrAc crystals and then 
passed through a 22-µm pore filter to sterilize it. After filtra-
tion, the concentration of UrAc was quantified and, when 
necessary, was increased to correct it and filtered again. 
Preparation of CaOx crystals
Solutions of calcium chloride (0.4 M, 100 mL) and dipo-
tassium oxalate (0.4 M, 100 mL; Merck EGaA) were added 
to 300 mL distilled deionized water at a constant rate of 1 
mL/min, for 2 h. This suspension was continuously stirred 
for 5 h at 75°C, and then washed with deionized water 
to remove excess KCl. The remaining saturated solution 
was stored at 37°C for 15 days to allow CaOx crystalliza-
tion. The resulting CaOx crystals (0.1 g) were sterilized in 
ethylene oxide or in a steam autoclave, and suspended in 
culture medium without FBS (100 mL). The suspension 
(1000 µg/mL) was sonicated for 15 min to reduce particles 
to a uniform size.
Exposure of MDCK cells to noncrystalline UrAc and 
CaOx crystals
Hyperuricemia is characterized by serum UrAc con-
centrations above 70 µg/mL for men and 60 µg/mL for 
women and the concentration of 80 µg/mL was chosen for 
the experiments.
Prior to the experiments, cells were transferred to a 
six-well plate (1 x 106 cells/well) or to culture flasks and 
maintained under the culture conditions for 3 days. At 
confluence, MDCK cells were exposed for 24 h to DMEM 
(without FBS, control), DMEM containing noncrystalline 
UrAc (80 µg/mL) or lipopolysaccharide (LPS) (100 µg/mL) 
or CaOx (100 µg/mL). 
Noncrystalline UrAc and CaOx crystal endocytosis
CaOx and UrAc endocytosis was determined by flow 
cytometry. Briefly, the flow cytometer detects how the cell 
interacts with a focused laser beam in terms of how the 
cell scatters the incident light and emits fluorescence. In 
forward scatter, light is diffracted at low angles, generally 
proportional to cell size and the side scatter light is reflected 
at high angles, proportional to cell granularity and complexity 
and detected at 90° to the incident light axis (20).
Cultures of MDCK cells were exposed to CaOx (100 µg/
mL) and UrAc (80 µg/mL) as described above. After 24-h 
incubation, the cells were washed with PBS and incubated 
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with the trypsin-EDTA (0.25%) solution (Cultilab, Brazil). 
This procedure yields only cells containing internalized or 
strongly adherent crystals. Cell suspensions were trans-
ferred to conical fluorescence-activated cell sorter (FACS) 
tubes and immediately analyzed with a FACScan flow 
cytometer (FacsCalibur analyzer; Becton-Dickinson Immu-
nocytometry Systems, USA). Data were acquired for up to 
5 x 103 cells from each sample. Light intensity histograms 
were constructed for each experimental situation, and the 
geometric mean of light intensity for the cell population was 
determined. CaOx crystals were excluded from analysis us-
ing a gated analysis method based on forward light scatter 
and side scatter. MDCK cell complexity (granularity) was 
considered as a control parameter and compared with cel-
lular complexity after CaOx or UrAc exposition.
Glycosaminoglycan extraction and quantification
MDCK (106 cells) were treated with noncrystalline UrAc 
(80 µg/mL) and LPS (100 µg/mL). At the same time, H235SO4 
(100 µCi/mL) was also added to the culture medium for the 
metabolic labeling of GAGs. After 24-h incubation at 37°C, 
the medium and cell extract were obtained as described (21). 
Briefly, the culture medium was collected (medium fraction) 
and, after three PBS washes, the cells were incubated with 
3.5 M urea in 50 mM Tris-HCl, pH 7.4, and scraped from the 
flask surface and transferred to a centrifuge tube. 
CS and HS (100 µg each) were added, as carriers, 
to each fraction. After the addition of 3 volumes of etha-
nol, the mixtures were maintained at -20°C for 24 h. The 
precipitates formed were collected by centrifugation and 
vacuum dried. 
For the extraction of GAG, the precipitates formed in 
each fraction were resuspended in 100 µL phosphate-
cysteine buffer (60 mM, pH 6.5) containing EDTA (20 mM) 
and 100 µg/mL papain (Sigma-Aldrich) and incubated at 
50°C overnight.
The compounds thus obtained were analyzed by a 
combination of agarose electrophoresis and enzymatic deg-
radation with specific mucopolysaccharidases (22,23).
The 35S-sulfate-labeled compounds were visualized by 
exposure of the agarose gel slabs (after fixation, drying, and 
staining) to a Packard Cyclone™ Storage Phosphor System 
(Packard Instrument, USA) for 1 day. For quantification, 
they were scraped off the agarose gels and counted with a 
Beckman 6800 liquid scintillation spectrophotometer (Beck-
man Coulter Inc., USA) using the Ultima Gold LSC-Cocktail 
(Perkin Elmer, USA) (24) and reported as cpm/106 cells. 
The quantitative results were corrected for 35S-decay. 
RNA isolation, reverse transcription and quantitative 
real-time PCR
Total RNA was purified from MDCK cells by the phenol 
and guanidine isothyocyanate-cesium chloride method 
using an appropriate kit (Trizol, Life Technologies, USA). 
Two micrograms of total RNA was treated with DNase (RQ1 
RNase - Free DNase, Promega, USA) to prevent genomic 
DNA contamination. The RNA pellet was resuspended in 
RNase-free water, and reverse transcribed into cDNA by the 
addition of 0.5 mg/mL oligo d(T), 10 mM DTT, 0.5 mM dNTPs 
(GE Healthcare, UK), and 200 U reverse transcriptase 
enzyme (SuperScript RT, Life Technologies).
Real-time amplification was performed with a GeneAmp 
5700 Sequence Detection System SDS (ABI Prism 7700, 
Applied Biosystems, Life Technologies, USA). Real-time 
PCR product accumulation was monitored using the in-
tercalating dye, SYBR Green I (Applied Biosystems, Life 
Technologies), which exhibits a higher fluorescence upon 
binding to double-stranded DNA. 
Relative gene expression was calculated using the 
conditions of the early stages of PCR, when amplifica-
tion was logarithmic and, thus, could be correlated with 
the initial copy number of gene transcripts. The reactions 
were cycled 40 times under the conditions previously 
determined by conventional PCR. Fluorescence for each 
cycle was quantitatively analyzed. At the end of the PCR, 
the temperature was increased from 60° to 95°C at a rate 
of 2°C/min, and fluorescence was measured every 15 s 
to construct the melting curve. A nontemplate control was 
run with each assay. 
Gene sequences were obtained from GenBank and PCR 
was performed with specific primers for COX-2, perlecan 
and β-actin. Primers were designed with the Primer Express 
software v2.0 from Applied Biosystems (Table 1). Results 
of 8 independent experiments per group are reported as 
relative expression normalized with the β-actin housekeep-
ing gene, used as an endogenous control. 
Table 1. Primer sequences, product size and annealing temperature for β-actin, proteoglycans and cyclooxy-
genase-2 (COX-2) genes. 
Gene Sequence (5’ to 3’) Product size (bp) Annealing temperature
COX-2 AAG TCC CTG AGC ATC TAC GGT TT 98 55°C
NM000963.2 GTT GTG TTC CCT CAG CCA GAT T
Perlecan TTT CGA GAG GTG TCC GAG GCT 256 58°C
NM005529.5 TTA TCT TGG GAA CTG GGG CAC
β-actin CCT CTA TGC CAA CAC AGT GC 191 56.9°C
EF156276.1 ACA TCT GCT GGA  AGG TGG AC
960 F.T. Borges et al.
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Real-time data analysis
The cycle threshold (Ct) values were subtracted from 
the Ct value for each gene (to give ΔCt values). These 
values were used for statistical comparisons. For graphic 
representation, the fold variation was then determined us-
ing the 2-(ΔΔCt) method according to published protocols 
(25) and manufacturer recommendations. Fold variation 
was calculated by determining the difference in ΔCt values 
between a chosen reference and test sample (ΔΔCt value), 
and applying the 2-(ΔΔCt) formula.
Cell viability experiments
Necrotic and apoptotic cells were identified us-
ing acrydine orange/ethidium bromide (Sigma-Aldrich) 
and HOESCHT 33342 (Bisbenzimide Hoe 33342 
(2’-[4-ethoxyphenyl]-5-[4-methyl-1-piperazinyl]-2,5’-bi-1H-
benzimidazole); Sigma-Aldrich) dyes, respectively. MDCK 
suspensions were centrifuged, resuspended in PBS and 
incubated with acrydine orange/ethidium bromide solution 
for 5-15 min. Cells were then observed under the light 
microscope. Ethidium bromide stains all cells green, while 
acrydine orange is excluded from viable cells. HOESCHT 
33342 stains the chromatin. Blue cells were considered to 
be non-apoptotic, and cells with condensed chromatin were 
considered to be apoptotic. At least 100 cells per culture 
were counted, and the results are reported as percent 
necrotic or apoptotic cells.
PGE2 production
The concentrations of PGE2 were assessed in cell 
cultures treated with noncrystalline UrAc alone or associ-
ated with LPS through commercial competitive ELISAs 
(Cayman Chemical, USA). All assays were performed ac-
cording to manufacturer protocols. The absorbance of each 
sample was read with the Ultra Microplate Reader EL808 
(Bio-Tek Instruments, USA) and is reported as picograms 
per milliliter. 
Statistical analysis
Data are reported as means ± SEM. Experimental 
and control groups were compared by the Student t-test. 
The level of significance was set at 5% (P < 0.05) in all 
analyses.
Results
The MDCK cell line synthesized a mixture of CS (32.5%) 
and HS (67.5%). Most of the GAGs were secreted into the 
culture medium, while smaller amounts were observed in 
the cell extract (Figure 1A). Noncrystalline UrAc (80 µg/
mL) significantly decreased the HS concentration of both 
the culture medium (2127 ± 377 cpm) and cell extract 
(1131 ± 273 cpm) compared to control culture medium 
(4447 ± 730 cpm) and cell extract (2148 ± 307 cpm), and 
also decreased CS concentration in the cell extract (285 
± 73 cpm) compared to control cell extract (669 ± 143). At 
higher concentrations of UrAc (200 µg/mL), there was no 
decrease in GAG synthesis. LPS, used as a positive control 
for inflammation, had no effect on CS or HS synthesis or 
secretion (Figure 1B).
Figure 2 shows the effect of noncrystalline UrAc on 
the expression of perlecan core protein. UrAc (80 µg/mL) 
decreased perlecan expression in MDCK (0.61 ± 0.13 ar-
bitrary units, AU) compared to the control situation (1.07 ± 
0.16 AU) but the higher concentration (200 µg/mL) did not 
show the same effect. These results agree with the find-
ings on HS synthesis shown in Figure 1. In contrast, UrAc 
had no significant effect on the expression of versican core 
protein (data not shown). 
There was no increase in necrotic (UrAc: 8.7 ± 1.7% 
vs control: 6.1 ± 1.9%) or apoptotic (UrAc: 6.1 ± 2.0% vs 
control: 6.8 ± 1.8%) rate after exposure to UrAc. Only very 
Figure 1. Effect of uric acid (UrAc) and lipopolysaccharide (LPS) 
on the synthesis of 35S-chondroitin sulfate (CS) and 35S-heparan 
sulfate (HS) in MDCK cells. MDCK cells exposed to DMEM with-
out FBS (control), UrAc (80 µg/mL) (A) or LPS, Escherichia coli 
0111:B4 (B) were incubated with H235SO4. After 24 h, the culture 
medium (1 mL) was collected and labeled “medium fraction”. The 
cells were treated with 3.5 M urea in 50 mM Tris-HCl, pH 7.4, and 
scraped from the flask surface. The solution was labeled “cell 
extract”. After addition of 3 volumes of ethanol, the mixtures were 
maintained at -20°C for 24 h, then centrifuged, vacuum dried, 
and the precipitates resuspended in 100 µL 60 mM phosphate-
cysteine buffer, pH 6.5, containing 20 mM EDTA and 100 µg/
mL papain at 50°C for 24 h. Aliquots of culture medium and cell 
extract of each experimental situation were submitted to agarose 
gel electrophoresis. The 35S-GAGs were identified and quanti-
fied. Results are reported as means ± SEM 35S-glycosamino-
glycans (35S-GAGs cpm/106 cells). Each assay was repeated at 
least six times. *P < 0.05 compared to control (Student t-test).
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high concentrations of UrAc (400 µg/mL) induced cell death 
by apoptosis in this cell line (data not shown).
In gout, UrAc accumulation is associated with inflamma-
tion. On the other hand, in the renal system, the mechanisms 
described for UrAc effects on proximal epithelial tubular cells 
include NF-kB, protein kinase C, MAPK and cPLA2 (19). 
In the present study, we tested the hypothesis that COX-2 
activation and its synthesis product prostaglandin could be 
related to the effect of noncrystalline UrAc in these cells. 
Figure 3 shows the effect of UrAc on COX-2 expression 
and PGE2 synthesis in MDCK cells. Noncrystalline UrAc 
(80 µg/mL) significantly increased COX-2 expression in 
these cells (5.63 ± 1.88 AU) compared to control (0.88 ± 
0.22 AU; Figure 3A).
UrAc significantly increased PGE2 production (439.5 
± 2.1 pg/mL) compared to control (178.4 ± 10.5 pg/mL) 
in this cell line (Figure 3B). This result agrees with COX-2 
expression induced by UrAc in this cell line.
The endocytosis of UrAc and CaOx crystals in MDCK 
cells was assessed by flow cytometry. CaOx (724.2 ± 4.2 
geometric mean), but not UrAc (80 µg/mL) increased MDCK 
cellular complexity when compared to the control situation 
(674.6 ± 4.6 geometric mean). After exposure to UrAc, there 
was a small but significant decrease in the endocytosis of 
CaOx (688.6 ± 5.4 geometric mean) in these cells. 
Discussion
The present study demonstrates that noncrystalline 
UrAc significantly decreases GAG and perlecan synthesis 
in Madin-Darby canine kidney cells. These effects could 
not be attributed to inflammatory induction or to the cell 
damage induced by UrAc. Furthermore, UrAc decreased 
CaOx crystal endocytosis, which could increase the CaOx 
availability in urine, and thus promote the aggregation or 
nucleation of CaOx crystals. 
Hyperuricemia is associated with the development of 
Figure 2. Effect of uric acid (UrAc) on perlecan mRNA expression 
in MDCK cells. Semi-confluent MDCK cells were treated with 80 
or 200 µg/mL UrAc for 24 h. Total RNA was purified and reverse 
transcribed into cDNA. PCR was performed with primers for per-
lecan. Real-time PCR product accumulation was monitored using 
the intercalating dye, SYBR Green I. The reactions were cycled 
40 times under the conditions described in the text. Fluorescence 
for each cycle was quantitatively analyzed and relative gene ex-
pression was calculated. A nontemplate control was run with each 
assay. Results of 8 experiments per group are reported as rela-
tive expression normalized with the β-actin housekeeping gene. 
Data are reported as means ± SEM arbitrary units (AU). *P < 0.05 
compared to control (Student t-test).
Figure 3. Effect of uric acid (UrAc) on messenger RNA (mRNA) 
expression of cyclooxygenase-2 (COX-2, A) and prostaglan-
din E2 (PGE2) production (B) in MDCK cells. A, Briefly, semi-
confluent MDCK cells were treated with UrAc (80 µg/mL) and/
or lipopolysaccharide (100 µg/mL) for 24 h. After this period, to-
tal RNA was purified and reverse transcribed into cDNA. PCR 
was performed with primers selective for COX-2. Real-time PCR 
product accumulation was monitored using the intercalating dye, 
SYBR Green I. The reactions were cycled 40 times under the 
conditions described in the text. Fluorescence for each cycle 
was quantitatively analyzed and relative gene expression was 
calculated. B, The concentrations of PGE2 were assessed with 
commercial competitive ELISAs and all assays were performed 
according to manufacturer protocols. Results of 8 experiments 
per group are reported as means ± SEM arbitrary units (AU) for 
PCR and picograms of PGE2 per milliliter for the ELISA assay. *P 
< 0.05 compared to control (Student t-test).
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renal stones, not only UrAc but also CaOx stones. Two 
theories have been proposed to explain this effect (26). 
The first proposes that urinary urate crystals could promote 
CaOx precipitation (27), and the second hypothesis is that 
urate reduces the inhibitory activity of urinary GAGs, which 
normally prevent CaOx crystallization (28).
The present study shows that noncrystalline UrAc sig-
nificantly decreases the synthesis and secretion into the 
culture medium of CS and HS by MDCK cells. Although 
GAGs present in human urine are CS and HS (8), possibly 
of systemic origin (10), the decrease in GAGs induced by 
noncrystalline UrAc in MDCK cells could inhibit the inter-
action between CaOx crystal and tubular epithelial cells, 
consequently favoring CaOx aggregation or nucleation.
Additionally, noncrystalline UrAc decreased the syn-
thesis of CS, but not the expression of versican in MDCK 
cells. Perhaps other CS-PG, such as biglycan and bamacan 
also expressed by this cell (21), could be decreased by 
noncrystalline UrAc stimulation. Also, high concentrations 
of UrAc (above, 200 µg/mL) did not decrease the synthesis 
of CS and HS proteoglycans, but high concentrations are 
not observed in clinical practice, suggesting that the effect 
observed in the present study was specific. 
An additional factor leading to the formation of UrAc 
or mixed uric acid/calcium salt stones is membrane injury 
(29). Damage to the cells lining the renal tubules may play 
an active role in creating the conditions for stone develop-
ment. In the present study, we did not observe any injuries 
induced by UrAc (80 µg/mL) in MDCK cells. UrAc induced 
significant necrosis and apoptosis only at very high con-
centrations (500 µg/mL) (data not shown).
It is becoming clear that noncrystalline UrAc has a direct 
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in CaOx endocytosis in the presence of UrAc. This decrease 
in CaOx endocytosis could contribute to the aggregation or 
nucleation of CaOx crystals in urine. Farell et al. (18) also 
analyzed the endocytosis of monohydrate CaOx (COM) 
crystals in MDCK cells exposed to UrAc. There was a 
significant increase in COM crystals induced by soluble or 
crystalline UrAc, but the study involved higher concentra-
tions of UrAc (500 µg/mL) and COM (200 µg/mL) than used 
in the present study. 
Taken together, our results demonstrate that UrAc has pro-
inflammatory effects, increasing COX-2 and PGE2 production, 
but decreases the synthesis of GAGs and perlecan by MDCK 
cells. They strongly suggests that UrAc could be implicated in 
renal disease progression, even at the mild levels of hyperu-
ricemia frequently observed in many diseases. 
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